In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed
Three years after Bayer and J&J began recruiting more than 7,000 patients for a big new Phase III study of Xarelto as preventive measure against …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
